NTRK2 and head and neck squamous cell carcinoma: In contrast to the previous experiments, the relative loss of TrkB expression initiated a more cisplatin sensitive response in HNSCC cells, with a nearly 66% reduction in IC50 value in the TrkB-knockdowns (Figures 5D and S1B).